8-K: InspireMD Announces Positive One-Year Follow-Up Results from C-GUARDIANS Clinical Trial

InspireMD's C-GUARDIANS clinical trial one-year follow-up results abstract has been accepted for presentation at LINC 2024, showing continued promise for their CGuard Prime Carotid Stent System.

Summary

• InspireMD announced that an abstract of the one-year follow-up results from its C-GUARDIANS IDE clinical trial has been accepted for presentation at the LINC 2024 conference.
• The C-GUARDIANS trial evaluated the CGuard Carotid Stent System for treating carotid artery stenosis.
• The trial enrolled 316 patients across 24 sites in the U.S. and Europe, including both symptomatic and asymptomatic patients.
• The primary endpoint included major adverse events like death, stroke, or myocardial infarction within 30 days, and ipsilateral stroke from 31 to 365 days.
• The 30-day results previously presented showed a DSMI rate of 0.95% in the Intent-To-Treat population and 0.63% in the per-protocol population.
• The company is optimistic that the one-year results will show a similar level of neuroprotection.
• If the results are positive, InspireMD plans to submit a Premarket Approval Application (PMA) later this year.
• A commercial launch of CGuard Prime in the U.S. is targeted for the first half of 2025, pending approval.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the acceptance of the one-year follow-up results abstract and the potential for a PMA submission and commercial launch. However, it also acknowledges risks related to future funding and regulatory approvals, which tempers the overall sentiment.

Positives

• The acceptance of the one-year follow-up results abstract at LINC 2024 is a positive step for the CGuard Carotid Stent System.
• The previously reported 30-day results showed very low DSMI rates, indicating the safety of the device.
• The company is optimistic about the one-year results, suggesting continued positive outcomes.
• The potential for a PMA submission later this year and a commercial launch in the U.S. in the first half of 2025 are positive milestones.

Risks

• The company's future success depends on the outcome of the one-year follow-up results.
• There is a risk that the one-year results may not be as positive as the 30-day results.
• The PMA submission and commercial launch are subject to regulatory approval, which is not guaranteed.
• The company faces risks associated with recurring losses, negative cash flows, and the need for additional capital.
• There are risks related to market acceptance, competition, and potential product liability claims.

Future Outlook

The company anticipates submitting a Premarket Approval Application (PMA) later this year and is targeting a commercial launch of CGuard Prime in the U.S. in the first half of 2025, pending regulatory approval.

Management Comments

• Marvin Slosman, chief executive officer of InspireMD, stated that they are very excited to announce that an abstract of the 12-month outcomes data from this important trial has been accepted for presentation at the upcoming LINC 2024 conference.
• Marvin Slosman also stated that they are optimistic that the results will show a similar level of neuroprotection, which may support a Premarket Approval Application (PMA) later this year and allow them to prepare for a commercial launch of CGuard Prime in the U.S. in the first half of 2025, if approved.

Industry Context

This announcement is significant in the vascular intervention field, as the CGuard system aims to improve stroke prevention outcomes. The presentation at LINC 2024, a major vascular intervention conference, highlights the importance of this trial within the industry.

Comparison to Industry Standards

• The 30-day DSMI rate of 0.95% in the Intent-To-Treat population and 0.63% in the per-protocol population are very low compared to historical rates for carotid artery stenting procedures.
• Typical rates for major adverse events in carotid stenting can range from 2% to 5% or higher, depending on patient risk factors and the specific device used.
• Companies like Abbott and Medtronic also have carotid stenting devices, and the results of the C-GUARDIANS trial will be closely watched to see how CGuard compares in terms of safety and efficacy.
• The presentation at LINC 2024 will provide a platform for comparison with other technologies and approaches in the field.

Stakeholder Impact

• Shareholders may react positively to the news of the abstract acceptance and potential PMA submission.
• Patients with carotid artery stenosis may benefit from the CGuard system if it receives regulatory approval.
• Employees of InspireMD may be positively impacted by the progress of the clinical trial and potential commercial launch.
• The medical community will be interested in the one-year follow-up results and their implications for stroke prevention.

Next Steps

• The company will present the one-year follow-up results at the LINC 2024 conference.
• InspireMD plans to submit a Premarket Approval Application (PMA) later this year.
• The company is preparing for a potential commercial launch of CGuard Prime in the U.S. in the first half of 2025, if approved.

Key Dates

Keywords

CGuard, Carotid Stent, Stroke Prevention, Clinical Trial, LINC 2024, PMA, Neuroprotection, C-GUARDIANS, InspireMD, Medical Device